Feldan Shuttle enables the delivery of a wide variety of protein payloads in different cell types, a versatility that allows the development of Shuttle-based treatment for various indications; to explore these avenues and maximise the potential of the Shuttle Platform, Feldan adopts a spin-out business strategy. New activities are continuously evaluated and developed to identify the most promising ventures that will be advanced through the clinical trial phases and filing of Biological License Application (BLA). Ultimately, these ventures could be out-licensed or grown as stand-alone entities separated from the parent company.
To put this strategy into action, Feldan is scouting for research groups that have identified medical targets and have generated disruptive pre-clinical results but lack the technological tools – i.e. the Shuttle platform – to translate these targets into therapies and enter clinical phases. Through these collaborations, Feldan will harness the unique expertise needed to translate Shuttle innovation into medical applications. This business model is aimed at lowering execution risk and maximising value and commercial success.
LEVERAGING OF THE PROTEIN SHUTTLE AND OUR PROTEIN PRODUCTION UNIT ALLOWS TO ACCELERATE THE DEVELOPMENT OF THERAPEUTICS APPLICATION
Feldan is currently establishing its therapeutic pipeline, which will consist of indications developed internally as well as in close collaborations with key-collaborators. The flexibility of the Feldan Shuttle platform allows us to pursue multiple therapeutic projects, a feature that will maximise value creation and lead to protein-based therapies that will improve the lives of patients around the world.
We are now developing two undisclosed therapeutic projects that will further confirm the ability of the Feldan Shuttle to act as a catalyst toward clinic trials for protein-based therapies. Furthermore, these first indications will become proof of concepts that will allow us to develop other human therapies centered on the use of the Shuttle and that will affect the same general mechanism (i.e. cell expansion, genome editing and transdifferentiation).